OmniAb (OABI) Insider Steven Love Buys 40,000 Shares
Insider Steven Love bought 40,000 shares of OmniAb, Inc. as other insiders also made trades on June 17, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Steven Love bought 40,000 shares of OmniAb, Inc. ($OABI) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OABI is up 12.3% after 1 week, up 4.4% after 1 month and up 126.1% to date (from the $2.03 close on Jun 17, 2026).
OABI
OmniAb, Inc.
Key Points
- Steven Love bought 40,000 shares of OmniAb, Inc. on June 17, 2026, when the stock was priced at $2.34, totaling about $93,600.
- On the same day, several insiders, including Steven Crouse and Philip Gotwals, sold 20,000 shares each of OmniAb.
- Analysts are optimistic about OmniAb, with ratings from firms like Leerink Partners and StoneX maintaining buy ratings and setting price targets of $12.00 and $6.00, respectively.
Get $OABI trade alerts by text
We text you when insiders, Congress or big funds trade $OABI. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated OmniAb, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at OmniAb, Inc.
Steven Love, an insider at OmniAb, Inc. (OABI), bought 40,000 shares on June 17, 2026. The shares were purchased at a price of $2.34, making the total value of this transaction about $93,600. This trade comes amid a flurry of insider activity at the company, suggesting ongoing interest from those close to the business.
Other Insiders Selling Shares
On the same day as Love's purchase, several other insiders sold shares of OmniAb. Steven Crouse, Philip Gotwals, and John Higgins each sold 20,000 shares. This activity reflects a mix of buying and selling among insiders, with Crouse and Gotwals also participating in the buying spree earlier that day.
Analysts Set New Price Targets
Analysts are showing a positive outlook for OmniAb, with firms like Leerink Partners and StoneX maintaining their ratings. On October 7, 2026, Leerink Partners maintained an "Outperform" rating with a price target of $12.00, up from $10.00. Meanwhile, StoneX also kept a "Buy" rating but raised its target from $4.00 to $6.00. HC Wainwright & Co. reiterated a "Buy" rating with a target of $11.00 on August 17, 2026.
How OmniAb, Inc. Stock Has Traded
OmniAb's stock closed at $2.34 on June 17, 2026, which is well above its 52-week low of $1.30 but below its high of $5.43. The stock has been trading below its 200-day moving average of $2.29, indicating some volatility. Investors might find the current price appealing, especially with analysts projecting a mean price target of $8.40.
What OmniAb, Inc. Does
OmniAb, Inc. is a biotechnology firm based in Emeryville, California. The company specializes in developing antibody discovery technologies for the pharmaceutical and biotech industries. This focus on innovation in therapeutics underlines the importance of insider trades, as they can signal confidence in the company's future.
What's Ahead for OmniAb, Inc.
OmniAb is set to report its next earnings on November 4, 2026. As the company prepares for this event, analysts and investors will be watching closely for any further developments and insider transactions. The recent trades provide a glimpse into the actions of those who are most familiar with the company's operations, but it's essential to remember that these filings reflect past decisions and may not represent current positions.
Related Filing Alerts
Source: Steven Love's Form 4 filing on $OABI (Jun 17, 2026). Find the original filing: OABI Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts